title: Partial vision recovery after iatrogenic retinal artery occlusion.
abstract: BACKGROUND
  To describe the first case of partial vision recovery in a 32-year-old woman with iatrogenic retinal artery occlusion (RAO) following glabella calcium hydroxylapatite (CaHA) injection, and to explore appropriate diagnostic and therapeutic measures according to a literature review.
  
  
  METHODS
  A 32-year-old woman had left eye RAO and a bilateral visual field defect after CaHA injection into the glabella region. Topical and systemic intraocular pressure lowering agents, isovolemic hemodilution, globe massage, and anticoagulation with acetylsalicylic acid were prescribed. Carbogen inhalation and oral corticosteroids were also given. In addition to the above therapies, hyperbaric oxygen therapy (HBOT) was implemented as adjuvant treatment. The final best corrected visual acuity (BCVA) of the left eye improved from hand motion at 15 cm to 0.1. Improved retinal circulation and decreased retinal vessel leakage were found in the follow-up fluorescein angiography. However, there were still multiple emboli in the conjunctival and retinal arteries.
  
  
  CONCLUSIONS
  This is the first case report on partial recovery of BCVA after iatrogenic RAO following cosmetic CaHA injection. Because no reliable treatments have been reported for such complications, HBOT may be considered as an alternative adjuvant therapy.
authors.forename: Shu-Fang
authors.initials: SF
authors.lastname: Hsiao
authors.affiliation: Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng Li Rd, Tainan, Taiwan. jackhyh@gmail.com.
authors.forename: Yi-Hsun
authors.initials: YH
authors.lastname: Huang
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage; D001672:Biocompatible Materials; D017886:Durapatite / Q000009:adverse effects*; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids; D006438:Hemodilution; D006801:Humans; D006931:Hyperbaric Oxygenation; D007049:Iatrogenic Disease; D007429:Intraocular Pressure; D008297:Male; D008405:Massage; D020127:Recovery of Function / Q000502:physiology*; D015356:Retinal Artery Occlusion / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D041623:Tomography, Optical Coherence; D061205:Vascular Calcification / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D014786:Vision Disorders / Q000139:chemically induced / Q000503:physiopathology / Q000628:therapy; D014792:Visual Acuity / Q000502:physiology*; D014794:Visual Fields / Q000187:drug effects / Q000502:physiology
chemical_list: D000925:Anticoagulants; D000959:Antihypertensive Agents; D001672:Biocompatible Materials; D005938:Glucocorticoids; D017886:Durapatite